UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
_____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): December 2, 2019
ZOMEDICA PHARMACEUTICALS CORP.
(Exact Name of Registrant as Specified in Charter)
| Alberta, Canada | 001-38298 | N/A |
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number) |
| | | |
| 100 Phoenix Drive, Suite 190, Ann Arbor, Michigan | 48108 |
| (Address of Principal Executive Offices) | (Zip Code) |
| | | | |
Registrant's telephone number, including area code:(734) 369-2555
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
| | [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ X ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ X ]
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Shares, without par value | ZOM | NYSE American |
Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers;
As previously reported on Form 8-K on December 3, 2019, Dr. Johnny D. Powers, a director of the Company, was named as Strategic Advisor and will provide day-to-day strategic oversight and management guidance to Mr. Rampertab, the newly appointed interim-CEO.
Because of his role as a paid Strategic Advisor, Dr. Powers stepped down from his membership on the Audit Committee. Messrs. Jeffrey Rowe, James LeBar and Rodney Williams remain on the Audit Committee.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | ZOMEDICA PHARMACEUTICALS CORP. |
| | | |
| | | |
| Date: December 11, 2019 | By: | /s/ Shameze Rampertab |
| | | Name: Shameze Rampertab |
| | | Title: Chief Financial Officer and Interim CEO |
| | | |
